Skip to content

Zprávy skupiny

  • Aspen concludes strategic partnership with US-based Avion Pharmaceuticals
    on 12.11.2020

    Durban – United States-based Aspen Pharma USA Inc. and Aspen Global Incorporated, located in Mauritius, both wholly owned subsidiaries of Aspen Pharmacare Holdings Limited, have announced a license and commercialisation agreement with Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, for the exclusive rights to relaunch Cenestin® in the USA. This is a New Drug Application… The post Aspen concludes strategic partnership with US-based Avion Pharmaceuticals appeared first on Aspen Pharmacare.

  • Aspen announces agreement with Johnson & Johnson to manufacture investigational COVID-19 vaccine candidate
    on 02.11.2020

    Durban, South Africa – Aspen is pleased to announce that one of its wholly-owned South African subsidiaries, Pharmacare Limited (which trades as “Aspen Pharmacare”), has entered into a preliminary agreement with Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica NV, two of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the technical transfer and proposed commercial manufacture of their COVID-19 vaccine candidate, Ad26.COV2-S. The vaccine candidate is currently undergoing clinical trials. Aspen Pharmacare will perform formulation, filling and secondary packaging of the vaccine for supply to Johnson & Johnson. This agreement is still subject to the successful completion of the relevant technology transfer activities and finalisation of certain commercial manufacturing terms.  Aspen Pharmacare has agreed to provide the necessary capacity required for the manufacture of Johnson & Johnson’s COVID-19 vaccine candidate at its existing sterile facility in Port Elizabeth, South Africa. Aspen has invested in excess of R3 billion in the facility together with the high technology equipment and systems that will be used to manufacture state-of-the-art sterile drugs and vaccines, packaged into vials, ampoules and pre-filled syringes. The production area where it is intended that the vaccine candidates will be manufactured has capacity to produce more than 300 million doses per annum. The facility has accreditation from a range of international regulatory authorities and provides lifesaving medicines to both the domestic and international markets. It was part of the first flagship investments announced at the President’s inaugural South African Investment conference. Stephen Saad, Aspen Group Chief Executive said “We have invested globally in our sterile capability and are determined to play a role in the manufacture of vaccines to add to our proud track record of making contributions to humanity in times of global pandemics. This has included, inter alia, being a leading global supplier for antiretrovirals for the treatment of HIV/AIDS, multi-drug-resistant-TB products and COVID-19-related treatments such as anaesthetics and dexamethasone. We have been selected as a vaccine partner by Johnson & Johnson and this project will receive priority focus. We are particularly pleased to be given the opportunity of providing assistance for patients in need across the world from our South African base."         The post Aspen announces agreement with Johnson & Johnson to manufacture investigational COVID-19 vaccine candidate appeared first on Aspen Pharmacare.

  • Aspen increases revenue by 9% to R38,6 billion
    on 09.09.2020

    Johannesburg - JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced reviewed provisional Group financial results for the year ended 30 June 2020. COMMENTARY RESHAPING OF THE GROUP The recently announced agreement to divest the assets related to the commercialisation of Aspen’s Thrombosis business in Europe to Mylan (refer SENS announcement of 8 September 2020) marks the end of the process to reshape the foundation of the Group. Following the completion of this transaction, Aspen’s Commercial Pharmaceuticals business will be heavily weighted towards territories where we have demonstrated capabilities and a strong performance record, largely in Emerging Markets. A higher proportion of our business will be exposed to the private sector and will be better positioned to benefit from the expanding middle classes in Emerging Markets, where our trusted and proven brands are well placed to support the increasing medical demands of these growing populations. The receipt of the proceeds from the aforementioned transaction with Mylan will again give us scope for acquisitive investment to support initiatives aimed at enhancing value in areas of strength. Our significant investment in capital expenditure to build our sterile manufacturing capacities has been slightly delayed by the COVID-19 pandemic. This investment is planned to peak in the year ahead before reducing rapidly in subsequent years as the projects reach their end. The complex and niche production capabilities installed will allow us to reduce cost of goods within our existing portfolio. It also allows us to leverage this sought after capacity, particularly with big pharma, to further expand our global presence in steriles thus enhancing our offering of quality, affordable medicines. As a result of our reshaping of the Group and our significant investment in sterile manufacturing, Aspen is highly differentiated from our peer group as it is the most Emerging Market-focused specialty pharmaceutical company and a global leader in the production of sterile products. COVID-19 IMPACT The COVID-19 pandemic has created great uncertainty and many challenges for people and companies across the globe. Despite this, Aspen’s business model has proven resilient. Our relevant product portfolio, effective business continuity plans and safety measures to protect our employees have enabled us to remain in full operation throughout this period. We are most proud of the commitment shown by all of Aspen’s employees, with special gratitude to those at the production sites, for ensuring we have been able to maintain the supply of essential medicines to COVID-19 and other patients around the world under these circumstances. The volatility associated with the pandemic has had an adverse impact on our results in the second half of the 2020 financial year. This impact has varied by timing and region. The hard lockdown in China significantly restricted sales of medicines there for at least three months. Conversely, early in the first wave we experienced a spike in demand for certain of our medicines, most notably in South Africa, Australia and Mexico. This was followed by the predicted drop in demand as the resultant abnormally high inventory in-market levels were normalised. In Europe, there was a significant need for our sterile products required to treat COVID-19 patients during the height of infections, but a decline in orders for products related to elective surgeries. The period after the first wave has been characterised by continued social distancing, leading to reduced infection rates in non-COVID-19 communicable diseases and a slow and uncoordinated resumption of elective surgeries which has adversely impacted our performance. Despite the many challenges experienced during the second half of the financial year, we have made great progress against each of our medium-term priorities, while maintaining the supply of our medicines to patients in need around the world. GROUP PERFORMANCE (CONTINUING OPERATIONS) Group revenue increased 9% to ZAR 38,6 billion and Normalised EBITDA increased 7% to ZAR 11,0 billion for the 12 months ended 30 June 2020. The increase in Group revenue was supported by growth from Commercial Pharmaceuticals (+6%), despite the difficult trading conditions, and a pleasing performance from Manufacturing (+22%). Normalised headline earnings per share (NHEPS) increased 9% to ZAR 14,65, favourably impacted by lower financing costs. Strong second half cash flows resulted in a positive cash inflow from working capital for the 12 months ended 30 June 2020 and supported a cash conversion rate of 142%. Net borrowings declined ZAR 3,8 billion to ZAR 35,2 billion. The strong cash generation was offset by ZAR 5,6 billion in unfavourable currency movements. The leverage ratio in terms of the Facilities Agreement of 2.89 times is comfortably below the covenant leverage ratio of 3.5 times. Testing of intangible and tangible assets for impairment has resulted in impairments of ZAR 1,5 billion arising primarily from a decline in the outlook for the affected products. Discontinued operations include the Nutritionals Business, the Asia Pacific non-core pharmaceutical portfolio, both divested in the 2019 financial year, as well as the Japanese Business and the Public Sector ARVs. The Japanese business divestment became effective on 31 January 2020. The South African Public sector ARV transaction with Laurus, a leading Indian producer of ARV APIs, became effective in June 2020. Material relative movements in exchange rates in the last four months of the financial year have had a positive impact on financial performance, as is illustrated in the table below (which compares performance in the prior comparable period at previously reported exchange rates and then at constant exchange rates (“CER”)). The CER results for the 12 months ended 30 June 2019 restate the performance for that period using the average exchange rates for the 12 months ended 30 June 2020.   For the 12 months ended 30 June 2020   Continuing operations Reported FY 2020R'million Restated ReportedFY 2019^ R'million Change at reportedrates % Restated CER FY2019 ^ Change at CER %   Revenue 38 647 35 514 9% 37 320 4%   Normalised EBITDA * 10 968 10 277 7% 10 699 3%   NHEPS ** (cents) 1 464,6 1 344,8 9% 1 397,7 5%   ^ FY 2019 has been restated as a result of discontinued operations * Operating profit before depreciation and amortisation adjusted for specific non-trading items as defined in the Group’s accounting policy. ** NHEPS are HEPS adjusted for specific non-trading items, being transaction costs and other acquisition and disposal-related gains or losses, restructuring costs, settlement of product related litigation costs, net monetary adjustments and currency devaluations relating to hyperinflationary economies and significant once-off tax provision charges or credits arising from the resolution of prior year tax matters. SEGMENTAL PERFORMANCE (CONTINUING OPERATIONS AT CER) Commercial Pharmaceuticals Commercial Pharmaceuticals, which comprises Aspen’s Regional Brands and Sterile Focus Brands, grew 1% to ZAR 31,1 billion. Gross profit declined 3% to ZAR 17,1 billion on lower margins from Regional Brands (refer below). Regional Brands Regional Brands revenue increased 3% to ZAR 16,9 billion. Revenue was adversely impacted by reduced demand during the lockdown period. In these circumstances, Sub-Saharan Africa (+6%), Latin America (+10%) and MENA (+8%) all delivered excellent growth. Gross profit percentage was adversely impacted by the increased cost of doing business under COVID-19, the recall of Zantac in Australia and generic competition placing pricing pressure on the oncology portfolio in Europe CIS. Sterile Focus Brands Despite heightened demand for certain Anaesthetics Brands used in the clinical management of COVID-19 patients, the postponement of elective procedures negatively impacted the Sterile Focus Brands segment. Revenue from Sterile Focus Brands, comprising Anaesthetics and Thrombosis Brands, decreased 1% to ZAR 14,3 billion, primarily due to the lost sales in China during the hard lockdown period. Europe CIS revenue was flat while good growth was achieved in Latin America and MENA. Despite the adverse effect of the material slowdown in China and the higher cost of goods sold for Thrombosis Brands (as guided), the gross profit percentage remained stable. Manufacturing Manufacturing revenue increased 14% to ZAR 7,5 billion, benefitting from the increase in sale of heparin (+ZAR 668 million) and non-heparin based APIs to third parties. Gross profit percentage increased to 30,1% on improved production efficiencies. PROSPECTS While the underlying business has demonstrated good performance over the past year and is well positioned for this momentum to continue, the uncertainty created by the enduring unfavourable influence of COVID-19 is likely to impact results in the year ahead. As reported, the weakening of the ZAR against almost all of the basket of Aspen’s trading currencies has resulted in an uplift of our reported 2020 results. Should prevailing ZAR weakness persist, this uplift in earnings will be even more pronounced in the 2021 financial year. DIVIDEND TO SHAREHOLDERS Taking into account the uncertainty created by the current COVID-19 pandemic, notice is hereby given that the Board has decided that it would not be prudent to declare a dividend at this time. The Board will re-evaluate the circumstances regularly with a view to declaring a dividend when it is considered prudent to do so. The post Aspen increases revenue by 9% to R38,6 billion appeared first on Aspen Pharmacare.

  • Divestment of Aspen’s European Thrombosis Business to Mylan and withdrawal of cautionary
    on 08.09.2020

    Johannesburg – Following the release of a cautionary announcement on 24 August 2020, Aspen is pleased to announce that, Aspen Global Incorporated (“AGI”), its wholly owned subsidiary incorporated in Mauritius, has concluded an agreement in terms of which Mylan Ireland Limited (“Mylan”) will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis… The post Divestment of Aspen’s European Thrombosis Business to Mylan and withdrawal of cautionary appeared first on Aspen Pharmacare.

  • Aspen scoops prized Adam Smith Treasury Award
    on 22.07.2020

    Michael Shuttleworth, Aspen Group Treasury Executive Aspen’s Group Treasury Team was recently recognised when they were awarded the highly acclaimed Adam Smith 2020 Best In Class Treasury Solution In Africa Award. Gus Attridge, Aspen Group Deputy Chief Executive, shared in the good news of the award and said, “Congratulations Michael, and the whole Group Treasury team, for this well-deserved recognition.” Aspen's Group Treasury Team (l-r): Hymie Shapiro, Michael Shuttleworth and Crispen Katsukunya Michael Shuttleworth, Group Treasury Executive said, “We knew from the start that this was an ambitious project and there were times when it seemed like we wouldn’t get there. Winning the Adam Smith 2020 Best In Class Treasury Solution in Africa award is a shining testament to the innovation, dedication and teamwork of the many talented people at Aspen Pharmacare and BNP Paribas who were and continue to remain involved in the conception, design, implementation and running of this solution. I am immensely proud of what we have achieved.” The Adam Smith Awards are now in their 13th year and are recognised throughout the globe as the ultimate benchmark of corporate achievement. The standard of submissions this year was of the very highest level, with 187 nominations spanning 24 countries. The post Aspen scoops prized Adam Smith Treasury Award appeared first on Aspen Pharmacare.

Scroll To Top